Navigation Links
MIT chemists design new way to fluorescently label proteins
Date:6/1/2010

CAMBRIDGE, Mass. Since the 1990s, a green fluorescent protein known simply as GFP has revolutionized cell biology. Originally found in a Pacific Northwest jellyfish, GFP allows scientists to visualize proteins inside of cells and track them as they go about their business. Two years ago, biologists who discovered and developed the protein as a laboratory tool won a Nobel Prize for their work.

However, using GFP as a fluorescent probe has one major drawback the protein is so bulky that it can interfere with the proteins it's labeling, preventing them from doing their normal tasks or reaching their intended destinations.

"For a long time, people have been trying to find better ways to label proteins," says Katharine White, an MIT graduate student in the lab of Alice Ting, associate professor of chemistry.

Ting, White and their colleagues have now come up with a new way to overcome the disadvantages of GFP, by tagging proteins with a much smaller probe. Their probe allows proteins to carry out their normal functions, offering scientists the chance to glimpse never-before-seen activity.

The researchers describe the new technique, dubbed PRIME (PRobe Incorporation Mediated by Enzymes), in the Proceedings of the National Academy of Sciences this week.

First isolated from a jellyfish in 1962, GFP allows scientists to track otherwise invisible proteins as they move about the cell, orchestrating processes such as cell division and metabolism. To achieve this, scientists tack the gene for GFP onto the gene for the protein they want to study. After the engineered gene is introduced into cells, it will produce proteins that glow fluorescent green.

However, GFP's large size (238 amino acids) can interfere with some proteins, such as actin, a molecule that helps give cells their structure and is involved in cell division, motility and communication with other cells.

"People use fluorescent proteins to st
'/>"/>

Contact: Jennifer Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Chemists get grip on slippery lipids
3. Good earth: Brown chemists show origin of soil-scented geosmin
4. Team of chemists receives $5 million grant to develop enzyme mimics
5. Biochemists reveal details of mysterious bacterial microcompartments
6. Biologists are from Mars, chemists are from Venus?
7. Glowing films developed by UC San Diego chemists reveal traces of explosives
8. NIST chemists get scoop on crude oil from pig manure
9. Chemists make beds with soft landings
10. Biochemists manipulate fruit flavor enzymes
11. Smoke smudges Mexico Citys air, chemists identify sources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... tissue-engineered trachea (windpipe), utilising the patient,s own stem ... woman with a failing airway. The bioengineered trachea ... airway, thereby saving her life. These ... stem cells, combined with biologically compatible materials, can ...
... breakthrough against cancer, infectious diseases, or metabolic conditions like ... drugs, and even if they do clinical development usually ... medical research is conducted in highly fragmented groups focusing ... turn out not to work properly or to have ...
... created by a University of Central Florida professor show ... Professor James Turkson,s compounds disrupt the formation and spread ... The compounds, S3I-201 and S3I-M2001, break up a cancer-causing ... side effects so far. "The compounds are very ...
Cached Biology News:Adult stem cell breakthrough 2Adult stem cell breakthrough 3Systems biology brings hope of speeding up drug development 2Systems biology brings hope of speeding up drug development 3Two new compounds show promise for eliminating breast cancer tumors 2
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... 2015 GEA Pharma Systems, G-CON ... recipients of the INTERPHEX Exhibitor Awards for 2015 ... Portable, Continuous, Miniature and Modular (PCMM) platform. PCMM ... continuous processing equipment, smart control systems and PODs ... and inactive ingredients into bulk tablets. , ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Synedgen ... Nguyen, PhD as Regulatory Affairs Manager. , Dr. Nguyen ... an important juncture for the company as it moves ... drug products over the next two years. Dr. Nguyen ... of all the regulatory key documents that must be ...
(Date:5/4/2015)... , May 4, 2015 Many of ... But for certain infants with rare, inherited mutations ... stark consequences of their impaired immune responses. ... have identified an important role for calcium signaling ... Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Synedgen Announces the Appointment of Regulatory Affairs Manager 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
... Limited (NasdaqCM: PRAN) (ASX: PBT.AX), a biopharmaceutical,company ... treatments for,neurodegenerative disorders, today announced it has ... statements for the year ended,June 30, 2007, ... The annual,report its available on Prana,s website ...
... VaxGen,Inc. (Pink Sheets: VXGN) announced today that ... Directors as a result of accepting the CEO,position ... that Mr.,Anthony relinquish all corporate directorships in accepting ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) "On behalf of ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4Jack Anthony to Resign From VaxGen's Board After Accepting CEO Position at Osprey Pharmaceuticals 2
... tumor cells of embryonal carcinoma of testis and ... tumors like seminoma. Glandular epithelium of yolk sac ... endocrine cells of stomach and acini cells of ... Epitope: Carbohydrate portion on human embryonal ...
TP-1 (NDOG1)...
Ras-related C3 botulinum toxin substrate 1...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
Biology Products: